BLFS Shariah Compliance
Screening Methodology: AAOIFI
DOUBTFUL
Last Updated: March 03, 2026
Report Source: 2025 Annual Report
BioLife Solutions Inc. Stock Analysis BLFS
BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. The company is headquartered in Bothell, Washington and currently employs 155 full-time employees. The firm facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the cell and gene therapy market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal closed systems are purpose-built rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The firm's ThawSTAR product line comprises a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
Read More BioLife Solutions Inc (BLFS) Chart
Key Statistics of BioLife Solutions Inc (BLFS)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$20.85Volume
375.00KP/E Ratio (TTM)
-52 Week Range
Market Cap
1.05BAvg. Volume
376.83KDividend Yield
-Financial Metrics & Statements of BioLife Solutions Inc (BLFS)
FAQ's for BioLife Solutions Inc (BLFS)
- According to Musaffa’s Shariah screening methodology, BioLife Solutions Inc (BLFS) is currently classified as DOUBTFUL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.